Among patients with chronic immune thrombocytopenic purpura, the 1-year risks of cardiovascular (CV) events were 1% and 2%, and nearly 8% experienced a bleeding event. CV events occurred across all ...
—Caroline Kruse, President & CEO of the Platelet Disorder Support Association, discusses the importance of recognizing the limitations of existing ITP therapies and assessing fresh management ...
Novartis announced that the Food and Drug Administration (FDA) has approved Promacta (eltrombopag) for the treatment of thrombocytopenia in children aged ≥6 years with chronic immune thrombocytopenia ...
A panelist discusses how ITP creates a chronic inflammatory state causing underrecognized symptoms like fatigue and joint pain that significantly impact patients' quality of life and ability to ...
Basel, June 15, 2018 - Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results ...
Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality ...
The Japanese pharma is currently investigating mezagitamab’s potential in two late-stage autoimmune programmes.
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first ...
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the second dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results